Serina Therapeutics Inc (SER) Stock Analysis — PE Ratio, PS Ratio, Intrinsic Value & 2030 Price Target
Serina Therapeutics Inc stock (SER) is currently trading at $2.43. Serina Therapeutics Inc PS ratio (Price-to-Sales) is 236.17. Analyst consensus price target for SER is $11.00. WallStSmart rates SER as Sell.
- SER PE ratio analysis and historical PE chart
- SER PS ratio (Price-to-Sales) history and trend
- SER intrinsic value — DCF, Graham Number, EPV models
- SER stock price prediction 2025 2026 2027 2028 2029 2030
- SER fair value vs current price
- SER insider transactions and insider buying
- Is SER undervalued or overvalued?
- Serina Therapeutics Inc financial analysis — revenue, earnings, cash flow
- SER Piotroski F-Score and Altman Z-Score
- SER analyst price target and Smart Rating
Serina Therapeutics Inc
📊 No data available
Try selecting a different time range
Smart Analysis
Serina Therapeutics Inc (SER) · 8 metrics scored
Smart Score
Category Performance
WallStSmart pulls financial metrics like revenue growth, profit margins, and valuation ratios and scores each one from 0 to 10 based on how strong or weak it is. Those 10 scores are grouped into 4 categories: Growth, Profitability, Valuation, and Quality — which form the 4 axes of the spider chart you see. The categories are then combined into a final score out of 100, but not equally. Growth and Profitability together count for 60% of the total, because a fast-growing profitable business matters more than just a cheap one. That final number maps to a rating (Strong Buy, Buy, Hold, Avoid) and a letter grade, giving you one clear Stock Rating.
Investment Thesis
Strong fundamentals in revenue growth. Concerns around market cap and return on equity. Significant fundamental concerns warrant caution or avoidance.
Serina Therapeutics Inc (SER) Key Strengths (1)
Revenue surging 154.90% year-over-year
Supporting Valuation Data
Serina Therapeutics Inc (SER) Areas to Watch (7)
Company is destroying shareholder value
Losing money on operations
Earnings declining -43.50%, profits shrinking
Very expensive at 236.2x annual revenue
Very expensive at 22.0x book value
Very low institutional interest at 4.05%
Micro-cap company with very limited liquidity and high volatility
Supporting Valuation Data
Serina Therapeutics Inc (SER) Detailed Analysis Report
Overall Assessment
This company scores 19/100 in our Smart Analysis, earning a F grade. Out of 8 metrics analyzed, 1 register as strengths (avg 10.0/10) while 7 fall into concern territory (avg 1.3/10). The category breakdown reveals uneven performance, with some areas requiring attention.
The Bull Case
The strongest argument centers on Revenue Growth. Growth metrics are encouraging with Revenue Growth at 154.90%.
The Bear Case
The primary concerns are Return on Equity, Operating Margin, EPS Growth. Some valuation metrics including Price/Sales (236.17), Price/Book (21.99) suggest expensive pricing. Growth concerns include EPS Growth at -43.50%, which may limit upside. Profitability pressure is visible in Return on Equity at -485.40%, Operating Margin at -18869.00%.
Key Dynamics to Monitor
Three factors to monitor going forward. First, whether Return on Equity improves, as this is the primary drag on the overall score. Second, margin trajectory, with Return on Equity at -485.40% needing improvement to support the investment thesis. Third, growth sustainability, with Revenue Growth at 154.90% strong but requiring continuation.
Risk Considerations
Based on the metric profile, this is a higher risk investment. There are more areas of concern than strength, warranting a more conservative position size. Investors should size positions according to their risk tolerance and maintain diversification.
Bottom Line
Fundamental challenges outweigh strengths at current levels. Return on Equity and Operating Margin are the primary drags. Consider waiting for meaningful improvement before committing capital.
Disclaimer: Smart Analysis is a scoring system developed by WallStSmart Team. Scores update daily using multi-model valuation framework. Always conduct your own research and consult with financial advisors before making investment decisions.
SER Price-to-Sales(PS) Ratio Chart
Historical valuation based on market cap ÷ trailing 12-month revenue
SER's Price-to-Sales ratio of 236.17x trades at a 24% premium to its historical average of 190.36x (75th percentile). The current valuation is 80% below its historical high of 1188.34x set in Jun 2025, and 18496% above its historical low of 1.27x in Feb 2024. Over the past 12 months, the PS ratio has compressed from ~1018.9x as trailing revenue scaled faster than the stock price.
WallStSmart Analysis Synopsis
Data-driven financial summary for Serina Therapeutics Inc (SER) · HEALTHCARE › BIOTECHNOLOGY
The Big Picture
Serina Therapeutics Inc is in a high-growth phase, prioritizing rapid expansion over margins. Revenue reached 116,000 with 155% growth year-over-year. The company is currently unprofitable, posting a 0.0% profit margin.
Key Findings
Revenue growing at 155% YoY, reaching 116,000. This pace significantly outperforms most BIOTECHNOLOGY peers.
Spending 3133% of revenue (4M) on R&D, reinforcing its commitment to innovation and future growth.
Free cash flow is -4M, meaning the company is burning cash. This may be acceptable for high-growth companies investing heavily.
Earnings fell 44% YoY while revenue grew 155%. This gap usually reflects one-time items (tax benefits, write-offs) in the prior period, not an operational decline.
What to Watch Next
Growth sustainability: can Serina Therapeutics Inc maintain 155%+ revenue growth, or will competition slow it down?
Sector dynamics: monitor BIOTECHNOLOGY industry trends, competitive moves, and regulatory changes that could impact Serina Therapeutics Inc.
Bottom Line
Serina Therapeutics Inc is a high-conviction growth story with revenue accelerating at 155% while profitability is still developing. For growth-oriented investors, the trajectory is compelling. For value investors, the thin 0.0% margins and premium valuation suggest patience until the unit economics mature further.
This synopsis is generated from publicly available financial data. It is not financial advice. Always conduct your own research and consult a qualified financial advisor before making investment decisions.
Insider Transactions
Loading insider activity...
About Serina Therapeutics Inc(SER)
NYSE MKT
HEALTHCARE
BIOTECHNOLOGY
USA
Serina Therapeutics Inc is a forward-thinking biotechnology company focused on developing innovative therapies for unmet medical needs, particularly in oncology and neurology. Leveraging its proprietary polymer-based drug delivery platform, Serina enhances therapeutic efficacy to improve patient outcomes. With a robust pipeline of product candidates, the company is well-positioned for sustainable growth in the biopharmaceutical sector. Its dedication to advanced technology and strategic collaborations reflects its commitment to transforming healthcare solutions and creating value for investors.